The Blue Jays' recent re-signing of Josh Fleming on a minor league deal is an intriguing move, especially given the team's current pitching struggles. Fleming, a left-handed reliever, has a history of inconsistent performance, which raises questions about his potential impact on the team. In my opinion, this move is more about filling a gap in the roster than providing a reliable solution to the team's pitching woes. Fleming's previous stint with the Blue Jays was short-lived, and his performance in the majors has been underwhelming, with a 4.77 ERA and 4.65 FIP. While he may offer some depth, his ability to consistently eat innings is questionable. The team's current situation is dire, with several key pitchers on the injured list, including Bowden Francis, Cody Ponce, Shane Bieber, Trey Yesavage, and Jose Berrios. Max Scherzer, who has been pitching through forearm tendinitis, could also join the injured list soon. This creates an opportunity for Fleming to step up, but his past performance suggests that he may not be the reliable option the team needs. The Blue Jays have other options, such as Yariel Rodriguez, Lazaro Estrada, and Adam Macko, who can provide multi-inning relief work or spot starts. Fleming's re-signing may provide some short-term relief, but it is unlikely to be a game-changer for the team's pitching struggles. The Blue Jays need to look beyond this move and address the underlying issues that have plagued their pitching staff this season. In my view, this move is a temporary fix, and the team needs to re-evaluate its strategy to ensure long-term success.
